Lawyers are now reviewing cases against Ozempic. Patients report serious problems after using the drug. These issues include vision loss, stomach paralysis, and blocked bowels.
Ozempic is a drug approved to treat type 2 diabetes. Many people also use it for weight loss. New studies show it can cause gastroparesis. This condition stops the stomach from moving food properly.
The warning label on Ozempic failed to alert users. It did not mention these risks. Patients may qualify for money through a lawsuit.
Multiple drugs are now part of this legal fight. These include Ozempic Wegovy Rybelsus Trulicity and Mounjaro. A class action lawsuit began in early 2024. It is now called MDL No. 3094 in the Eastern District of Pennsylvania.
Key Case Facts
-
Active Lawsuit: 1882 as of June 2025
-
Focus: Vision loss and stomach problems
-
Main Issue: Failure to warn about dangerous side effect
-
Drugs Involved: Ozempic Wegovy Mounjaro Rybelsus
Injuries Under Review
Lawyers are only taking cases with these conditions:
-
NAION (a vision-loss disorder)
-
Gastroparesis needing hospital care
-
Bowel blockage or ileus
Recent Update
June 17 2025
Twenty-one people in New Jersey want to group their NAION lawsuits. They say Ozempic and Wegovy caused their blindness. The cases may become a new multicounty litigation.
Vision loss claims are now gaining attention. Gastroparesis started the fight. But NAION claims seem more severe. Permanent blindness can bring huge damages. It also raises public concern.
June 12 2025
There are now 1,882 cases in the main MDL. Most deal with stomach injuries. Vision lawsuits are rising, but they are not part of this MDL yet.
More lawsuits are expected after the Daubert ruling. That decision will determine if expert testimony can go to trial.
June 10 2025
Doctor want the FDA to add a black box warning. They say Ozempic may cause sudden vision loss. A new Danish study and JAMA reports support this claim.
A stronger warning could change how doctors prescribe the drug. It could also help lawsuit that claim the company failed to inform user.
June 2 2025
Novo Nordisk started pushing back. The company says other health problems, like diabetes or high blood pressure, caused the eye issues. Lawyers say that does not matter. The company still had a duty to warn.
Some people lost vision without any history of eye disease. That weakens the defense. Juries may not believe that this is just bad luck.
Settlement Predictions
Some severe cases may settle for $200,000 to $500,000. Eye injury claims could be worth more. If a plaintiff proves total blindness, the amount may pass $1 million.
Mild cases will likely settle for much less. Quick recovery lowers the value.
Weight loss users may get higher payouts. Many are younger and healthier. Juries may believe the drug caused the problem more easily. Also, these patients often did not need the drug. That fact could lead to larger awards.
FDA Action and Legal Impact
In September 2023 the FDA issued a new warning for Ozempic. The warning focused on a serious risk called ileus. Ileus is a condition that block the intestine. It can stop food and liquid from moving through the digestive tract.
This condition causes intense pain. Patient also report nausea vomiting bloating and constipation. Some cases require emergency care or hospitalization. In rare case ileus can lead to life threatening complication.
The FDA did not ban Ozempic. Instead, it added this risk to the drug’s label. That change may seem small. But it matters a lot in court.
The new warning shows the FDA saw a real safety problem. It also proves the drugmaker had enough data to update the label. That fact helps plaintiffs in court. It supports the idea that Novo Nordisk knew about this danger long ago.
Even with this update, the company still failed in key ways. The label does not connect these symptoms to gastroparesis. It also does not appear in the “Warnings and Precautions” section where doctors usually look.
This choice seems intentional. It allows the company to protect sales. But it leaves patients in the dark.
Lawyers now argue this delay and omission add up to negligence. The FDA label change is not just a regulatory move. It is now a central piece of evidence in the lawsuits.
Courts may use it to show that Ozempic’s risks were not only real, but also avoidable. That could raise settlement values and increase pressure on the drugmaker.
Legal Claims Against Novo Nordisk
Every lawsuit claims the company hid major risks. Plaintiffs say Novo Nordisk knew Ozempic could cause serious harm. They point to studies, reports, and real patient cases. Still, the company never gave clear warnings.
Ozempic slows how the stomach moves food. This effect can lead to gastroparesis. That is a painful condition with long-term effects. The stomach stops working right. Patients vomit food that never digests. Many lose weight fast. Some end up in the hospital.
The drug’s label never warned about this. It mentioned minor issues like nausea or constipation. It briefly noted slower digestion. But it left out gastroparesis completely. That missing detail misled doctors. It also kept patients from making informed choices.
The lawsuits say this was not a mistake. The legal team argues the company made a choice. Profit came first. Warning labels might have hurt sales. So they downplayed real dangers to protect revenue.
Also, the label changes over time raise new questions. Earlier versions included more safety info. Then some of that info disappeared. Lawyers claim this pattern shows intent. The company wanted to hide how bad the side effects really were.
Every lawsuit pushes one core point. The company failed to warn. That failure caused real harm. People suffered. Some still suffer. And Novo Nordisk must take responsibility.
How the MDL Helps Victims
The MDL system makes the legal process more efficient. It stands for Multidistrict Litigation. This system brings similar lawsuits into one court. Right now, that court sits in the Eastern District of Pennsylvania.
This setup benefits both sides. Lawyers avoid repeating the same work in every case. Judges don’t hear the same motions again and again. It saves time and money. It also leads to faster rulings on key issues.
The biggest benefit goes to the victims. The MDL creates more pressure on the drugmaker. One strong ruling can affect hundreds of cases. That risk pushes the company to settle. It often leads to higher payouts, too.
Each plaintiff keeps an individual case. They still get to tell their story. Their injury, their proof, and their facts matter. The MDL just makes the road shorter.
Evidence from one case can help all. Expert reports, safety data, and company emails only need to be shown once. Then other plaintiffs can use that same information.
The MDL also makes the company respond faster. Public attention builds. Investors watch closely. Media covers every hearing. That spotlight matters. Drug companies often want these cases to go away before they hurt their brand.
In the end, the MDL gives victims more leverage. It also cuts delays. That combination brings hope to patients who need justice—and compensation.
When Will Ozempic Cases Settle?
No one can give an exact date. The legal process is still at the start. Courts are now reviewing expert testimony. They want to see if the science behind the claims is strong enough.
Bellwether trials have not begun. These early trials help both sides predict how juries may react. They often set the tone for future settlements. Until those trials happen, little movement is expected.
Most legal experts think the first payouts won’t come before 2026. That’s a long wait. Larger settlements may take even more time. Mass tort cases often stretch over several years.
Still, pressure is growing. Ozempic continues to make billions in profit. Every lawsuit, every headline, adds more risk. The company has a lot to lose if the public turns against the drug.
Big verdicts could damage the brand. They could also open the door to more claims. That fear may force the company to settle sooner. Protecting the product’s reputation may matter more than fighting in court.
In the end, time will tell. Victims should stay informed and prepared. The path may be slow, but strong legal action is underway.
